Oncotelic Therapeutics, Inc. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Oncotelic Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2026-03-31 was $2.59M.
- Oncotelic Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2021-09-30 was $23.64K.
- Oncotelic Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2021-06-30 was $70.00K.
- Oncotelic Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2019-03-31 was $418.14K, a 159.45% increase year-over-year.
- Oncotelic Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2025 was $1.85M.
- Oncotelic Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2021 was $193.64K.
- Oncotelic Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2019 was $418.14K, a 44.39% decline from fiscal 2018.
- Oncotelic Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2018 was $751.88K.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2026-03-31 | $2.59M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $1.85M 10-K · filed 2026-04-15 | |
| 2021-12-31 | $193.64K 10-K/A · filed 2023-04-20 | |
| 2021-09-30 | $23.64K 10-Q · filed 2022-11-18 | |
| 2021-06-30 | $70.00K 10-Q · filed 2022-11-18 | |
| 2019-12-31 | $418.14K 10-K · filed 2021-04-15 | |
| 2019-03-31 | $418.14K 10-Q · filed 2020-11-16 | |
| 2018-12-31 | $751.88K 10-K · filed 2020-05-14 | |
| 2018-09-30 | $170.42K 10-Q · filed 2019-11-19 | |
| 2018-06-30 | $134.53K 10-Q · filed 2019-11-19 | |
| 2018-03-31 | $161.16K 10-Q · filed 2019-11-19 |